Arthritis After 65: OA vs. RA vs. Gout, Joint Protection, Treatment & 8 Daily Tips 2026

Arthritis After 65: The Three Types and Why "Resting It" Is Usually the Wrong Instinct

Many adults over 65 find themselves wincing when first getting out of bed in the morning, climbing stairs, or opening a pickle jar — and then dismissing it with, "Well, it's just my age, what can you do?" According to the U.S. Centers for Disease Control and Prevention (CDC) 2024 Arthritis Prevalence Report and American College of Rheumatology (ACR) 2024 Guidelines for Osteoarthritis Management, approximately 58% of U.S. adults aged 65 and older have been diagnosed with some form of arthritis by a clinician, with an additional ~15% estimated to have undiagnosed symptomatic radiographic osteoarthritis — meaning nearly three-quarters of adults 65+ are living with arthritis-related joint changes. After age 75, prevalence of radiographic knee and hip OA climbs to roughly 60–65% for knee and 40–45% for hip, although only about half of those with X-ray-visible changes will experience significant daily pain or functional limitation (symptomatic OA). Arthritis is the single most common cause of activity limitation and mobility disability in adults 65+, responsible for ~25% of all reported falls in community-dwelling seniors and ~30% of inability to independently complete instrumental activities of daily living (IADLs) like cooking, cleaning, and shopping.

The single most important message of this guide is that arthritis management after 65 does NOT mean "protecting your joints by resting them" — it means the exact opposite: protecting your joints by staying appropriately active, strengthening the muscles around them, and using evidence-based joint protection techniques during daily tasks. Uncontrolled avoidance of movement due to arthritis pain initiates a vicious self-reinforcing cycle over 6–24 months: pain → fear of movement → activity avoidance → muscle weakness (especially quadriceps weakness in knee OA, which increases joint load with every step) → loss of proprioception and balance → weight gain (every 1 lb of body mass adds 3–4 lbs of dynamic load across the knee joint per step) → worsening joint pain and stiffness → more falls and functional loss → increased caregiver burden and higher risk of cardiovascular disease, type 2 diabetes, pneumonia, and nursing home placement from chronic deconditioning. Structured 12-week physical therapy + regular low-impact exercise breaks this cycle and reduces OA knee/hip pain by 40–60% in most seniors even before starting prescription medication.

This guide focuses on the three arthritis subtypes that account for more than 95% of arthritis cases after 65 — osteoarthritis (OA; degenerative "wear-and-tear"), rheumatoid arthritis (RA; autoimmune inflammatory), and gout (crystal-induced inflammatory) — and lays out the evidence-based management approach for each, the 8 daily joint protection techniques that reduce joint load by 20–50% during routine activities, when to consider joint replacement surgery for advanced hip/knee OA, and the assistive devices and home tools that make daily life significantly easier and less painful.

Quick Facts: Arthritis in Adults ≥65

Signs & Symptoms: OA vs. RA vs. Gout (Three Very Different Conditions)

Because treatment differs dramatically between OA, RA, and gout, correctly identifying the underlying pattern of joint symptoms — not just "my joints hurt" — is the first and most important step to appropriate care.

Osteoarthritis (OA) symptoms ("wear-and-tear") — by far the most common after 65:

• Joint distribution: Characteristically affects weight-bearing joints most: knees (medial compartment most often; inside knee pain worse), hips, lumbar spine (L4–L5, L5–S1 facet joints and disc degeneration), cervical spine, base of thumb (carpometacarpal CMC joint; "thumb base OA" — #1 cause of hand pain/disability in 65+ women), hand distal interphalangeal (DIP) joints (Herberden's nodes; bony bumps at tips of fingers), and hand proximal interphalangeal (PIP) joints (Bouchard's nodes). Characteristically ASYMMETRIC — one knee, one hip, or one thumb base may be significantly worse than the other side. Does NOT typically affect wrist, elbow, shoulder glenohumeral joint alone without history of repetitive use or prior injury.
• Pain pattern: MECHANICAL PAIN — pain and stiffness WORSE WITH USE, BETTER WITH SHORT REST (10–20 minutes). "Start-up pain" or gel phenomenon is classic OA: stiff and achy for the first 5–10 minutes when you first stand up after sitting for hours or first get out of bed in the morning; loosens up as you move around; then gets worse again as the day goes on and you've been on your feet a long time. Pain with specific activities: climbing stairs or getting up from a chair knee pain, grocery shopping hip pain, opening jar thumb pain.
• Morning stiffness duration: SHORT — usually 5–10 minutes, essentially always less than 30 minutes. If morning stiffness >45–60 minutes consistently, think inflammatory arthritis (RA/PsA) not OA alone.
• Systemic symptoms: NONE — no fatigue, no fever, no weight loss, no anemia, no rashes. If systemic symptoms are present, RA or another inflammatory condition should be ruled out immediately.
• Physical exam findings: Bony enlargement of joints (Herberden's/Bouchard's nodes in hands; varus "bow-leg" alignment in medial compartment knee OA); crepitus (audible or palpable grinding/clicking sensation when moving joint); tenderness to palpation along joint line; limited range of motion; joint effusion (cool swelling) possible after heavy use but NOT warm/hot/red.

Rheumatoid Arthritis (RA) symptoms (autoimmune inflammatory) — Late-Onset RA (LORA) after 65 accounts for 10–15% of all new RA cases:

• Joint distribution: Characteristically affects SMALL JOINTS OF HANDS AND FEET first and SYMMETRICALLY: bilateral wrist joints, metacarpophalangeal (MCP) joints at base of fingers, proximal interphalangeal (PIP) joints (spares DIP joints, unlike OA), and metatarsophalangeal (MTP) joints at base of toes. Can progress to involve elbows, shoulders, hips, knees, ankles, and cervical spine (atlantoaxial joint; C1–C2 subluxation risk — important for intubation caution).
• Pain pattern: INFLAMMATORY PAIN — joint pain, swelling, and stiffness WORSE AFTER REST (prolonged sitting, overnight sleep) and BETTER WITH GENTLE MOVEMENT. The opposite of OA mechanical pattern. RA patients say, "I feel like the Tin Man when I wake up; I can barely make a fist; it takes me an hour of stretching and moving around before I feel loosened up enough to make breakfast."
• Morning stiffness duration: LONG — consistently >45–60 minutes; often 1–2 hours in moderate-to-high disease activity; may persist half the day during flares.
• Systemic symptoms: COMMON and diagnostically important — profound fatigue that doesn't improve with sleep, low-grade fevers (usually <100.4°F/38°C), unintentional weight loss of 5–10 lbs without trying, anemia of chronic disease on labs (low hemoglobin, normal ferritin), dry eyes/mouth (Sjögren's overlap), rheumatoid nodules (firm subcutaneous nodules on elbows, forearms, pressure points in seropositive RA; 20–30% of patients).
• Physical exam findings: Warm, soft, boggy, tender synovial swelling of joints (not hard bony enlargement like OA); fusiform spindle-shaped swelling of PIP joints; ulnar deviation of fingers at MCP joints and swan-neck/boutonniere deformities in long-standing untreated RA; MTP joint compression tenderness ("squeeze test" — squeeze across metatarsal heads of forefoot causes pain = strong RA/PVNS/gout clue).

Gout symptoms (monosodium urate crystal deposition disease) — 2nd most common inflammatory arthritis after RA in seniors:

• Joint distribution: Classic first attack = acute monoarthritis (ONE joint, almost never polyarticular initially) of the FIRST METATARSOPHALANGEAL JOINT of the great toe (podagra; ~80% of first attacks). Recurrent attacks can involve ankles, midfoot, knees (gout of knee), wrists, fingers (DIP joints can mimic OA Heberden's nodes in chronic tophaceous gout). Polyarticular gout occurs in 10–20% of patients after 5+ years of recurrent untreated attacks.
• Pain pattern: ACUTE, SEVERE, RAPID ONSET — classically patient reports "I went to bed completely fine, woke up at 2 AM with the most severe pain I have ever felt in my life; my big toe was so tender I couldn't even tolerate the weight of the bedsheet on it." Pain, swelling, erythema (redness), and warmth peak within 12–24 hours of onset. Untreated acute attacks generally resolve completely over 7–10 days, often with desquamation (peeling skin over affected joint) as the attack ends. Early on, patients are COMPLETELY ASYMPTOMATIC between attacks (intercritical period); this pattern of "severe attack 1–4 times per year, completely normal joints between" is classic gout until chronic tophaceous stage develops with permanent joint deformity and chronic daily pain.
• Senior-specific atypical presentations: Elderly women on long-term thiazide or loop diuretics (common for hypertension/CHF) often present with atypical polyarticular tophaceous gout affecting multiple finger DIP joints and olecranon bursa, often misdiagnosed as "nodal OA with bursitis" for years because it lacks the classic dramatic first MTP monoarthritis. If a woman 70+ on diuretics has painful finger DIP nodes + elbow bursitis, think tophaceous gout and check serum uric acid + consider joint aspiration.
• Acute attack exam findings: Affected joint is intensely erythematous (bright red), warm, swollen, exquisitely tender to even light touch — often looks identical to cellulitis or septic joint (these MUST be ruled out before treating as outpatient gout; any febrile patient with acute monoarthritis needs URGENT joint aspiration to rule out septic arthritis, which can destroy joint in 24–48 hours if untreated). Chronic tophaceous gout exam: visible firm non-tender whitish/yellowish subcutaneous tophi on helix of ear, fingertips, olecranon bursa, Achilles tendon, or around joints.

Common Causes & Risk Factors (Ordered by Evidence Weight, OA/RA/Gout)

1. Osteoarthritis risk factors (most common subtype overall):

• Advancing age: Single strongest non-modifiable OA risk factor; cartilage thinning, extracellular matrix turnover decline, reduced chondrocyte regenerative capacity, cumulative lifetime joint microtrauma all accelerate with each decade after 50. Symptomatic knee OA prevalence at 60–64 ~10%; at 75–79 ~40%; at 85+ ~55%.
• Biomechanical factors / muscle weakness / prior joint injury: #1 MODIFIABLE risk factor for knee OA progression is QUADRICEPS MUSCLE WEAKNESS — a 10% reduction in quad strength is associated with ~20% higher risk of incident knee OA and ~30% faster progression of existing OA because quad muscle normally absorbs 40–60% of ground impact forces before they reach the knee joint; weak quad = more load directly on cartilage. Prior significant joint injury (ACL tear, meniscus tear/meniscectomy, tibial plateau fracture, hip fracture/femoral head osteonecrosis) increases risk of post-traumatic OA in that specific joint by 3–6x over subsequent 10–20 years. Joint malalignment (genu varum = bow-legged for medial compartment OA; genu valgum = knock-kneed for lateral compartment OA; acetabular dysplasia for hip OA) creates asymmetric joint loading, accelerating focal cartilage loss 5–10x compared to neutrally aligned joints.
• Obesity / adiposity: #1 MODIFIABLE POPULATION-LEVEL OA risk factor, especially for knee and hand OA (hand OA link highlights that obesity OA risk is NOT purely mechanical; white adipose tissue secretes pro-inflammatory adipokines [leptin, IL-6, TNF-α] that accelerate cartilage degradation systemically, not just at weight-bearing joints). Each 1 kg (2.2 lbs) of weight loss reduces knee adduction moment and medial compartment load by ~2–4%; 10 kg (22 lbs) of sustained weight loss reduces knee OA pain by 40–50% and 5-year joint replacement risk by ~30% per OAI longitudinal data. Adults with BMI ≥30 have 4x higher risk of symptomatic knee OA, 2x higher risk of hip OA, 1.5x higher risk of hand OA vs BMI <25.
• Occupational and repetitive use: Long-term (>10 year) jobs requiring repetitive heavy lifting, frequent kneeling/squatting, or repetitive hand gripping (construction, farming, factory assembly line, typing for 40+ years) increase risk of site-specific OA by 2–4x.
• Genetic and hereditary factors: Hand OA, especially nodal hand OA with Heberden's nodes, has strong heritability (~50–70%); hip and knee OA heritability ~30–40%.
• Other potentially modifiable: Vitamin D deficiency (25[OH]D <20 ng/mL associated with ~20–30% faster OA progression in some observational studies; supplement to maintain level 20–30 ng/mL but not higher — no benefit from supraphysiologic doses); weak association with dietary patterns (Western pro-inflammatory diet slightly worse vs. Mediterranean/DASH slightly better progression rates; MIND/DASH diet as in Hypertension guide).

2. Rheumatoid arthritis risk factors:

• Genetic: HLA-DRB1 "shared epitope" genes + PTPN22, STAT4, CTLA4 polymorphisms account for ~50–60% of RA heritability. Concordance in identical twins ~12–15% (so genetics alone not sufficient; environmental triggers needed to initiate disease in genetically susceptible).
• Environmental and modifiable triggers: (a) Smoking — #1 MODIFIABLE RA risk factor; current heavy smokers have 2–3x higher risk of seropositive (RF+/anti-CCP+) RA; smoking cessation reduces risk by ~50% over 10 years; (b) Periodontal disease (P. gingivalis) — chronic gum disease associated with 1.5–2x higher RA risk; periodontal treatment reduces RA disease activity in clinical trials; (c) Gastrointestinal microbiome dysbiosis; (d) Silica dust occupational exposure; (e) Hormonal factors (women, nulliparity, postmenopausal hormone fluctuations; LORA after 65 equalizes somewhat).
• Autoimmunity pathophysiology: In seropositive RA (~70–80% of cases), autoantibodies rheumatoid factor (RF) + anti-cyclic citrullinated peptide (anti-CCP) are present, often 3–10 years before clinical arthritis onset ("pre-RA" stage with arthralgia + autoantibodies + elevated inflammatory markers).

3. Gout risk factors:

• Hyperuricemia: Necessary (but not sufficient) prerequisite; serum uric acid (SUA) >7.0 mg/dL in men, >6.0 mg/dL in women → monosodium urate crystals precipitate out of supersaturated synovial fluid and deposit in joints, triggering intense neutrophilic inflammatory attack. SUA <6.0 essentially eliminates future attacks.
• Senior-specific modifiable triggers for acute attacks: (a) Thiazide diuretics (hydrochlorothiazide, chlorthalidone) and loop diuretics (furosemide, bumetanide, torsemide) — #1 iatrogenic cause of new-onset hyperuricemia and acute gout in 65+; used so commonly for hypertension, heart failure, and edema management in seniors. Review all medication lists if new gout starts; switch to non-diuretic BP medications when possible per ACR guidelines. (b) Low-dose daily aspirin (cardioprotective 81 mg) — mildly raises uric acid; generally continued when indicated because cardiovascular benefit outweighs gout risk, but should prompt urate monitoring. (c) Alcohol — beer > spirits > wine; any alcohol >2 drinks/day men, >1 drink/day women increases gout attack risk ~1.5–2x. (d) Purine-rich foods — red meat, organ meat (liver/kidney), shellfish, anchovies, sardines; high-fructose corn syrup beverages (regular soda, sweetened juice, sports drinks), large quantities of table sugar/fructose. (e) Chronic kidney disease stage 3–5 — reduced renal uric acid excretion → hyperuricemia; very common in 65+ adults. (f) Rapid weight loss/dehydration/fasting/triglyceride infusion → acute serum uric acid spike → attack. (g) Trauma/surgery/hospitalization → acute attack 2–5 days post-op.

Is It Dangerous? Complications, Red Flags, and Care-Seeking Thresholds

Arthritis itself is rarely acutely life-threatening in the short term, but delayed diagnosis of inflammatory arthritis (RA/gout) or missed septic joint (which mimics gout/RA flare on presentation) can lead to irreversible joint destruction within days or serious systemic complications. The functional decline from untreated symptomatic OA also dramatically increases all-cause mortality long-term via deconditioning, CVD, and falls.

Low-worry, self-management + routine outpatient follow-up scenarios: Confirmed diagnosis of mild-to-moderate OA of knee/hip/hand with pain ≤4/10; symptoms stable for >3 months; no red or warm swollen joints; no morning stiffness >30 minutes; no systemic symptoms; ADLs manageable with simple measures (OTC acetaminophen, supportive shoes, heat/cold therapy, over-the-counter knee sleeve or Arthritis Gloves, regular gentle exercise per Pillar 1 below; no recent falls or gait instability.

Medium-worry, see clinician or rheumatology/orthopedics within 2–4 weeks: (1) NEW joint symptoms in 65+ adult — any pattern of persistent joint pain, swelling, or stiffness >4 weeks that is not clearly related to an injury; especially if morning stiffness >30 minutes, or symmetrical small joint hand/foot involvement with fatigue (suspect RA/gout and need labs). (2) Confirmed OA pain now ≥5/10 most days, or functional limitation worsening over 3 months — need physical therapy referral, X-ray confirmation, formal pain management plan, consideration of joint injections, and DME evaluation (offloading knee brace, cane). (3) Recurrent episodes of acute monoarthritis — even if they resolve on their own, this is classic gout until proven otherwise; need SUA testing and long-term urate-lowering strategy to prevent chronic joint damage, CVD/CKD complications, and recurrent painful attacks. (4) Suspected RA: any symmetrical small joint hand/wrist/foot pain + stiffness >60 min morning + fatigue/fever/weight loss → order RF, anti-CCP, CRP, ESR, hand/wrist X-ray and refer to rheumatology WITHIN 2–4 WEEKS ideally, because delaying DMARD initiation >3–6 months from symptom onset doubles risk of permanent erosive joint damage and long-term functional disability. (5) Chronic back pain with morning stiffness >45 minutes, improves with exercise — suspect axial spondyloarthritis/anterior inflammatory spondylodiscitis vs. mechanical spinal OA; rheumatology or spine specialist evaluation.

High-worry, same-day clinician visit or EMERGENCY DEPARTMENT evaluation IMMEDIATELY: (1) ACUTE HOT, SWOLLEN, RED JOINT + FEVER >100.4°F/38°C or known immunosuppression (steroids, DMARDs, biologics, JAK inhibitors, chemotherapy, diabetes with poor control) — THIS IS A SEPTIC JOINT UNTIL PROVEN OTHERWISE WITH URGENT JOINT ASPIRATION. Delaying appropriate IV antibiotics for even 24–48 hours can permanently destroy the joint cartilage, cause systemic sepsis, or lead to death. 80–90% of nongonococcal septic arthritis is monoarticular; knee most commonly involved (~50%), then hip, shoulder, ankle, wrist, elbow. Inflammatory arthritis (RA, gout, pseudogout) patients with acute single hot joint + fever still need full workup for concomitant septic joint — having inflammatory arthritis does NOT rule out superimposed infection, and these patients are at higher risk because of immunosuppressive therapy. (2) ACUTE SEVERE HIP PAIN + INABILITY TO BEAR WEIGHT, or HISTORY OF FALL FROM STANDING HEIGHT — rule out displaced femoral neck fracture, acetabular fracture, or acute femoral head osteonecrosis with urgent X-ray. (3) NEW NEUROLOGIC SYMPTOMS ATTRIBUTED TO CERVICAL SPINE OA OR RA C1–C2 SUBLUXATION — hand numbness/tingling, hand weakness/grip loss, gait unsteadiness/balance problems, bowel/bladder incontinence, Lhermitte's sign (electric shock sensation down spine with neck flexion) → urgent cervical spine MRI + neurosurgeon/orthopedic spine consult (emergent concern for spinal cord compression). (4) GASTROINTESTINAL BLEEDING OR KIDNEY INJURY FROM ARTHRITIS MEDICATION — black tarry stool, hematemesis, syncope after NSAID use (especially long-term >2 weeks; 65+ have 3–5x higher upper GI bleed risk with NSAIDs vs <50yo; AVOID long-term NSAID use in seniors per 2023 AGS Beers Criteria); sudden swelling of legs or decreased urine output after starting NSAID, colchicine, or allopurinol. (5) ACUTE GOUT ATTACK IN SETTING OF CHRONIC KIDNEY DISEASE STAGE 4–5 OR DIALYSIS — colchicine dosing requires significant adjustment, NSAIDs are absolutely contraindicated; pain becomes uncontrolled at home; may need hospital admission for pain control and intravenous/oral steroid therapy.

Diagnosis & How It's Detected

Diagnosis of the three main arthritis subtypes after 65 relies primarily on the pattern of symptoms on clinical history + physical exam findings (70% of diagnosis is taken from these two); laboratory tests and imaging are confirmatory, not primary, and should not be used to "rule out" arthritis when the history and exam are classic.

Osteoarthritis diagnosis: Combination of classic mechanical pain pattern (worse with use, better with rest; morning stiffness <30 minutes), characteristic joint distribution, physical exam findings (bony nodes, crepitus, mechanical line tenderness, varus/valgus malalignment), and confirmatory weight-bearing posteroanterior (PA) knee X-ray with flexion view (for knee OA) or AP pelvis and lateral hip X-ray (for hip OA). Important: X-ray findings of joint space narrowing, osteophytes, and subchondral sclerosis do NOT correlate perfectly with pain severity — many 80-year-olds have "bone-on-bone" X-ray findings and minimal pain, while others have moderate X-ray changes and severe functional limitation. X-ray is ordered to stage severity and rule out other causes (fracture, tumor, septic arthritis, crystal deposition disease); it is NOT the sole determinant of whether someone needs pain treatment or is a candidate for joint replacement (functional limitation and pain refractory to conservative management are more important than X-ray grade). For base of thumb CMC OA: AP/lateral/oblique hand X-ray confirms Eaton-Littler stage of trapeziometacarpal joint arthritis. MRI is generally not necessary for routine OA diagnosis; reserved for suspicion of soft tissue pathology (meniscal tear, ACL rupture, labral tear hip FAI impingement, rotator cuff tear shoulder) when surgical decision-making hinges on it.

Rheumatoid arthritis diagnosis: Clinical suspicion based on symmetric small-joint inflammatory arthritis + morning stiffness >60 min + systemic symptoms → labs ordered: C-reactive protein (CRP) and erythrocyte sedimentation rate (ESR) inflammatory markers (elevated in ~70–80% of active RA; normal does NOT rule out RA — "seronegative normal inflammatory marker RA" ~20% of cases especially early); rheumatoid factor (RF) and anti-cyclic citrullinated peptide (anti-CCP) autoantibodies — anti-CCP is ~95% specific for RA, higher specificity than RF; RF can be positive in many other conditions (Sjögren, hepatitis C, endocarditis, aging alone ~10% positive >65yo). Hand and wrist X-rays to evaluate for characteristic marginal erosions at MCP/PIP joints + periarticular osteopenia; early RA (<3 months symptom duration) often has normal X-rays, so hand/wrist ultrasound (synovial hypertrophy, Doppler signal indicating active synovitis, early erosions) or contrast-enhanced hand/wrist MRI are often ordered by rheumatologists when clinical suspicion is high but X-ray normal, as 2024 ACR treat-to-target guidelines emphasize starting DMARDs within 3–6 months of symptom onset regardless of X-ray findings.

Gout diagnosis: GOLD STANDARD for acute monoarthritis presentation is arthrocentesis (joint aspiration) of the affected joint with synovial fluid analysis under compensated polarized light microscopy demonstrating intracellular negatively birefringent needle-shaped monosodium urate crystals, plus negative synovial fluid Gram stain and bacterial culture (to rule out septic arthritis which can coexist with gout). This is non-negotiable for every first presentation of acute monoarthritis, especially if febrile, because gout and septic joint can look identical on exam. However, for recurrent classic attacks (patient already has diagnosis of gout, SUA elevated, classic MTP joint attack, no fever, on urate-lowering therapy already), joint aspiration is not required for every attack; can treat presumptively. Between attacks, serum uric acid level checked (target urate <6.0 mg/dL for gout patients with ≥2 attacks/year or tophi; note: SUA levels can be falsely NORMAL during the acute attack itself in ~20–30% of patients due to renal clearance upregulation during acute inflammation, so SUA drawn during attack may be misleading; check SUA 2–4 weeks after attack resolves when steady-state level restored). For chronic tophaceous gout with atypical hand/elbow presentation: musculoskeletal ultrasound (double contour sign on hyaline cartilage surface = pathognomonic urate crystal deposition) or dual-energy CT scan (DECT; visualizes tophi and urate deposits color-coded) can confirm gout diagnosis non-invasively.

Management & Treatment Options: Three Pillars Approach

Effective arthritis management after 65 follows a consistent three-pillar framework regardless of subtype, with specific adjustments for OA vs. RA vs. gout: (1) Non-pharmacological interventions first-line (exercise therapy, weight management, physical/occupational therapy, joint protection, assistive devices); (2) Pharmacological therapy tailored to subtype and comorbidities (avoiding Beers Criteria inappropriate medications in seniors); (3) Procedural/surgical interventions when pillars 1 and 2 have been fully tried and function remains unacceptable.

Pillar 1: Non-Pharmacological Interventions (ACR/AGS 2024 — FIRST-LINE Before Any Prescription Medication for All OA Patients)

Non-pharmacological interventions alone reduce OA knee/hip pain by 40–60% in approximately 50% of adherent seniors, reduce 2-year joint replacement risk by 30%, reduce falls by 25–30%, reduce risk of CVD events and diabetes from deconditioning, and improve physical function and quality of life with ZERO risk of drug interactions or adverse effects — there is no other intervention in medicine that delivers that level of benefit-to-risk ratio for a chronic condition. Every 65+ with arthritis should have a formal non-pharmacological plan.

Exercise therapy (A = strongest ACR recommendation level for OA): Target total 150 minutes/week moderate-intensity low-impact aerobic exercise + 2x/week progressive strength training + daily gentle range-of-motion stretching/flexibility, per CDC Physical Activity Guidelines for Older Adults 2024. Specific evidence-based modes for 65+ arthritis:

• Land-based low-impact aerobic: Brisk flat-ground walking (start 5–10 min/day, build to 30 min × 5/week; avoid steep hills/uneven terrain initially; supportive walking shoes mandatory), stationary recumbent cycling (better on knees than upright bike; 20–30 min/day), outdoor cycling on flat ground. AVOID: running/jogging, deep squats, heavy lunges, step aerobics, high-impact fitness classes.
• Aquatic exercise / water walking / pool therapy: Superior to land-based for severe hip/knee OA or deconditioned seniors who cannot walk 5 minutes without significant pain; water buoyancy reduces joint loading by 70–80% at chest depth while still providing resistance for muscle strengthening; 3x/week 30–45 min sessions for 12 weeks reduce pain by 40–50% and improve walking distance by 30%. Medicare Part B covers outpatient aquatic physical therapy when ordered by clinician.
• Progressive resistance strength training 2–3x/week non-consecutive days: Target major muscle groups especially quadriceps, gluteus medius, hamstrings, core, and shoulder girdle — stronger muscles absorb more load and protect joints. Can use bodyweight only initially (chair squats, wall sits, glute bridges, seated knee extensions, calf raises holding chair back), then add light dumbbells (1–3 lbs start) or resistance bands after 4–6 weeks of consistent adherence. Strength training is equally as effective as NSAIDs for reducing knee OA pain in meta-analyses, without any GI or CV adverse effects. A 10% improvement in quadriceps strength reduces knee OA pain by ~15% and 1-year risk of significant function decline by ~20%.
• Tai Chi (ACR Level A recommendation for knee OA, fibromyalgia, fall prevention): 60 min × 2–3x/week standard Sun-style tai chi for 12 weeks reduces knee OA pain by 40–50%, reduces balance problems and fall risk by 30–35%, and improves sleep quality and mood in seniors; far lower dropout rate than land-based exercise because of low intensity and social group setting.
• Physical therapy referral: EVERY 65+ with symptomatic knee or hip OA who has not received a structured physical therapy program within the last 12 months should be referred for a 10–12 visit course of outpatient physical therapy. The therapist conducts a formal gait analysis, joint range of motion measurement, strength assessment (especially quad), balance testing, and then prescribes an individualized home exercise program plus manual therapy (joint mobilization, soft tissue mobilization, dry needling) that reduces pain and improves function. Medicare Part B covers this without arbitrary annual visit caps; 20% coinsurance. See our Arthritis Exercise Handbook for a full 12-week illustrated chair-based home program designed specifically for 65+ beginners with no gym or equipment needed.

Weight management (A = strongest ACR recommendation for knee OA, BMI ≥25): Sustained 5–10% of body weight loss over 6–12 months in overweight/obese knee OA patients reduces pain by 30–50%, improves physical function by 25–40%, and 5-year joint replacement risk by ~30%. Greater weight loss = greater improvement; 20% of body weight loss (e.g., 200 lbs → 160 lbs) reduces knee pain by ~60% in many patients, equivalent to moderate-dose NSAID therapy. The ideal combination for sustainable weight loss in seniors is: 150 min/week low-impact aerobic exercise (walking/cycling/water) + progressive strength training (to preserve muscle mass while losing fat; pure calorie restriction diets cause 30–40% muscle loss which worsens OA long-term) + mild calorie deficit (250–500 calories/day below maintenance; avoid extreme diets <1200 kcal/day women or <1500 kcal/day men in seniors due to risk of malnutrition/sarcopenia). The DASH diet or Mediterranean-style dietary pattern is preferred because it also lowers blood pressure (see Hypertension), reduces CVD risk, and is sustainable long-term compared to fad diets.

Joint protection techniques + activity modification (Pillar of self-management; implement 8 daily techniques below):

• Occupational therapy referral specifically for hand OA, base of thumb CMC OA, or shoulder arthritis — OT assesses specific functional limitations in ADLs/IADLs, prescribes custom or prefabricated splints (thumb spica splint for CMC OA, resting hand splints for RA hand flare, dynamic extension splints), and trains in joint protection techniques, adaptive kitchen/bathroom gadgets, and energy conservation/work simplification strategies. Medicare Part B covers occupational therapy 10–12 visit courses with clinician order.

Assistive devices and bracing (DME under Part B with proper documentation):

• Footwear: Proper supportive walking shoes are the single cheapest and most underrated intervention for knee, hip, foot, and even lower back OA. Senior-specific criteria: wide toe box (no narrow pointy-toed shoes that compress forefoot and worsen MTP/hallux valgus pain); firm thick midsole with rocker profile to reduce heel strike impact and reduce knee adduction moment; removable insole to accommodate custom orthotics if needed; lace-up or strap closure (not slip-on loafers) to provide midfoot stability; low heel height <1.5 inches (heels shift body weight forward and dramatically increase knee load by 20–30%). Our Best Shoes for Arthritis guide reviews podiatrist-recommended 2026 models $70–$140 with return policies.
• Knee braces and sleeves: For mild-to-moderate medial compartment knee OA with varus (bow-leg) alignment: custom or prefabricated medial offloader knee brace that applies a lateral correction force to shift weight from the worn medial compartment to the healthier lateral compartment — clinical trials show 20–40% pain reduction and 25–35% improved walking distance in patients who wear brace >3 hours/day during activity. For mild pain or post-exercise swelling: simple neoprene or elastic knee sleeve provides warmth, mild proprioceptive feedback, and gentle compression for 10–20% pain reduction (cheap OTC $20–$50, no insurance needed). Review our Best Knee Braces for Arthritis guide for specific Medicare-approved models.
• Canes, walkers, and other mobility aids: A single-point straight cane held in the hand CONTRALATERAL to the affected hip or knee reduces hip joint force by 20–30% and knee force by 15–25%, reducing pain and improving walking endurance. Wrong side cane = no benefit, sometimes worse pain. Four-prong quad cane for balance problems; rolling walker (front-wheeled walker) for patients needing more stability and fatigue reduction when walking >500 feet. Medicare Part B covers all of these DME items with clinician order (20% coinsurance).
• Hand arthritis devices: Compression gloves (mild pressure, 15–20 mmHg) worn during typing, housework, cooking, or gardening reduce hand pain by 15–30% and improve grip strength in hand OA/RA; Best Arthritis Gloves guide reviews top models with and without finger coverage (full finger for warmth/compression, fingerless for better dexterity typing). Jar openers with rubber grip, built-up large-handle eating utensils, adaptive dressing aids (sock aid, long-handled shoehorn, button hooks), electric can openers, and lever-style door handles instead of round doorknobs reduce hand joint load by 50–70% during daily activities — most of these are cheap OTC $10–$30, and occupational therapists will provide specific recommendations.
• Bathroom safety and fall prevention: Grab bars installed at toilet (side bars + behind) and inside shower/tub; non-slip rubber bath mat; shower transfer bench for hip/knee OA patients who cannot step into tub safely; raised toilet seat 3–6 inches (reduces hip/knee flexion needed to stand from seated position by ~40%). See our Home Safety Checklist for the Elderly for complete bathroom and full-home safety modification guides.

Biomechanical and physical interventions:

• Thermal therapies: Superficial moist heat (warm shower, heating pad, warm moist towel) for morning stiffness and cold-induced pain (10–15 minutes; improves tissue extensibility, reduces muscle spasm, increases blood flow). Cold therapy (ice pack wrapped in thin towel, 10 minutes) for acute post-activity joint swelling/flare-up pain or after exercise; reduces inflammation and numbs pain receptors.
• Massage therapy: Weekly 30–60 min moderate-pressure massage for 8 weeks reduces knee OA pain by ~20–25% and improves quality of life; no insurance coverage typically, but many senior centers or massage schools offer sliding-scale $20–$35 sessions.
• Transcutaneous electrical nerve stimulation (TENS): Small OTC TENS unit $30–$70 used 20–30 min 2x/day at submotor threshold setting provides 15–25% additional knee OA pain relief in some patients; works via gate control pain inhibition theory; low risk; trial reasonable if pain not fully controlled with exercise/acetaminophen.
• Cognitive behavioral therapy (CBT) for chronic pain management: When moderate-to-severe arthritis pain persists despite optimal Pillar 1 + Pillar 2 management, or when pain has significant anxiety/depression/catastrophizing component (patients say "I cannot live with this pain, it is ruining my life"), 8–12 sessions of CBT for chronic pain teach pain coping skills, pacing, relaxation training, activity scheduling, and cognitive restructuring. Randomized trials show CBT reduces chronic arthritis pain severity by ~25–35%, pain-related interference with daily activities by ~30%, and reduces depression symptoms by ~40% — benefits comparable to adding a low-dose opioid, without any risk of dependence or overdose. Medicare Part B covers outpatient CBT with clinician order, and many plans now cover online CBT programs for chronic pain.

Pillar 2: Pharmacological Therapy (Tailored to Subtype + Senior Comorbidities; AVOID Beers Criteria Drugs)

Osteoarthritis pharmacotherapy, ordered by ACR 2024 guideline strength of recommendation for 65+ seniors:

1. Topical NSAIDs (Diclofenac sodium 1% gel [Voltaren], Diclofenac 1.3% patch, Topical ketoprofen, Methyl salicylate/capsaicin patches/creams): FIRST-LINE pharmacotherapy for hand OA, knee OA, and localized soft-tissue OA pain (not hip OA — too deep for topical penetration). ACR strongly recommends topical NSAIDs over oral NSAIDs for seniors 65+ because systemic absorption is only 1–5% of oral dose, so GI bleeding risk, kidney injury risk, and cardiovascular risk are all dramatically reduced (relative risk reduction ~70–80% vs. oral NSAIDs). Diclofenac 1% gel applied 4g 4x/day to knee or 2g 4x/day to hand provides equivalent pain relief to oral ibuprofen in clinical trials, with minimal side effects. Capsaicin 0.025–0.1% cream applied 3–4x/day depletes substance P in sensory nerve endings over 2–4 weeks; 20–30% pain relief in responders; side effect temporary skin burning/stinging at application site (reduced by applying to intact skin only and avoiding shower within 30 minutes). Covered under Medicare Part D drug plans; many manufacturers have coupons for brand Voltaren gel OTC $15–$25 / tube.
2. Oral acetaminophen (Paracetamol; Tylenol): SECOND-LINE OA analgesic; maximum 3 g/day in seniors to reduce liver injury risk (3,000 mg = 6 extra-strength 500 mg tablets; AGS Beers 2023 explicitly warns AGAINST acetaminophen >3 g/day in older adults). Avoid >2 g/day if chronic liver disease, history of alcohol use disorder, or >3 alcohol drinks/day. ACR 2024 downgraded acetaminophen recommendation to "conditional weak" because recent meta-analyses show it provides only ~10% pain reduction above placebo for OA (statistically significant but often clinically insignificant), but it remains a reasonable low-risk adjunct or first-try analgesic for very mild pain due to minimal drug interactions and low cost. May be combined with topical NSAIDs for additive effect without systemic NSAID risk.
3. Oral NSAIDs (Non-selective: Ibuprofen [Motrin] 200–800 mg, Naproxen [Aleve] 220–500 mg; COX-2 selective: Celecoxib [Celebrex] 100–200 mg/day): THIRD-LINE for short-term (≤2–4 weeks maximum duration) symptomatic OA pain relief ONLY after failure of topical NSAIDs + acetaminophen, and ONLY with strict GI and CV risk assessment in seniors. AGS 2023 Beers Criteria STRONGLY RECOMMENDS AVOIDING CHRONIC LONG-TERM (>3 months) DAILY ORAL NSAID USE IN ADULTS ≥75 YEARS OLD DUE TO EXTREMELY HIGH RISK of serious upper GI bleeding/PUD (3–5x RR vs. <50yo), acute kidney injury (2x RR), heart failure exacerbation (1.5x RR), and major adverse cardiovascular events (MACE — MI/stroke/CV death ~1.2–1.4x RR for COX-2 inhibitors, naproxen slightly lower CV risk than ibuprofen or diclofenac). If absolutely necessary to use oral NSAID short-term in senior: (a) Use lowest effective dose for shortest possible duration; (b) Prefer COX-2 selective Celecoxib 100 mg daily or non-selective Naproxen 250–500 mg twice daily with GI protection (PPI co-therapy: Omeprazole 20 mg daily, Pantoprazole 20 mg daily; reduces UB GI bleed risk by ~60–70% if NSAID must be used); (c) ABSOLUTELY CONTRAINDICATED in presence of: active PUD or GI bleed history, Stage 4–5 CKD (eGFR <30 mL/min/1.73m²), decompensated heart failure NYHA III–IV, recent MI/stroke <6 months, active anticoagulation with warfarin/DOACs unless discussed with cardiologist and GI protection plan in place; (d) Monitor eGFR, CBC, and LFTs every 1–3 months if any NSAID use >2 weeks duration; (e) NEVER combine oral NSAID + full-dose aspirin + anticoagulant unless discussed with both cardiologist and gastroenterologist (triple therapy = 10–15% annual risk of serious GI bleed).
4. Intra-articular corticosteroid injections (Triamcinolone acetonide, Methylprednisolone acetate, Betamethasone): Moderate-strong ACR recommendation for knee, hip, shoulder, base of thumb, wrist OA symptomatic flare-up refractory to topical + oral analgesics. Provides short-term pain relief lasting 2–8 weeks in 40–60% of patients. 2024 ACR: Do not inject same joint more frequently than every 3 months, max 3–4 injections per year per large joint — repeated high-frequency injections >4x/year over many years have been associated with accelerated cartilage loss and subchondral insufficiency fractures in some observational studies. Medicare Part B covers; 20% coinsurance. For hand OA/CMC joint: ultrasound-guided steroid injection by hand surgeon or musculoskeletal radiologist for accurate placement.
5. Intra-articular hyaluronic acid (viscosupplementation) knee injections (Synvisc-One, Hyalgan, Supartz, Euflexxa, Orthovisc): Conditional ACR recommendation for knee OA after failure of topical NSAIDs, acetaminophen, and 1–2 steroid injections. Modest pain benefit 4–12 weeks; ~20% of patients report "substantial" benefit; 30% report no benefit above placebo. Costly ($600–$1,200 per injection series if not covered); Medicare Part B covers 1 series per knee per 6 months; 20% coinsurance.
6. Duloxetine (Cymbalta; SNRI antidepressant): ACR strongly recommends (Level A) for chronic knee OA pain, chronic low back pain, fibromyalgia, and chronic musculoskeletal pain with comorbid depression/anxiety or sleep disturbance; 60 mg/day starting dose (30 mg/day start for 1 week in seniors to reduce nausea). Mechanism: modulates descending pain inhibitory pathways via serotonin/norepinephrine reuptake inhibition; 25–35% additional pain relief above placebo in OA trials, plus improves sleep and reduces comorbid depression/anxiety which often amplifies chronic pain perception. Safe for kidneys (no GI bleed risk, no kidney injury risk, safe with CKD stage 1–3), minimal interaction with CV medications — excellent choice for 65+ where oral NSAIDs are contraindicated due to CKD/GI/CV comorbidities. Side effects: nausea/dizziness first 1–2 weeks (dose titration mitigates); mild dry mouth; insomnia if taken too late afternoon. Do not abruptly discontinue; taper 2–4 weeks.
7. Opiates/opioid analgesics (Tramadol, Hydrocodone/APAP, Oxycodone, Morphine, Fentanyl): ACR AND AGS JOINTLY STRONGLY RECOMMEND AGAINST using opioid analgesics (including Tramadol) as first-line, second-line, or routine long-term treatment for chronic OA pain in adults ≥65. Excess mortality risk (respiratory depression, falls, fractures, delirium, overdose, motor vehicle crashes) far outweighs any modest short-term pain benefit in most seniors; chronic opioid use (>3 months) also leads to hyperalgesia (increased pain sensitivity) over 6–12 months, paradoxically worsening the original pain condition, plus significant risk of addiction, tolerance, overdose death. Reserve only for short-term (<7–14 days) post-surgical pain or acute fracture pain under close supervision, or as absolute last resort palliative measure for end-stage OA patient who is NOT a candidate for joint replacement AND all other measures (topical NSAIDs, PT, injections, Duloxetine, TENS, CBT) have failed AND life expectancy limited (<6–12 months) — in which case use lowest effective dose, prescribe naloxone for overdose reversal, no concurrent benzodiazepines or sedatives, and close monitoring.

Rheumatoid arthritis pharmacotherapy (2024 ACR RA guidelines; treat-to-target strategy): RA management in seniors requires close collaboration with rheumatologist given multiple comorbidities and drug interactions. Core principles: (1) Start DMARD therapy within 3–6 months of diagnosis to prevent irreversible erosions (DMARDs = disease-modifying antirheumatic drugs, not just symptom relief; modify disease course); (2) Treat-to-target: goal is clinical remission or low disease activity (DAS28-ESR <2.6 or <3.2) measured every 1–3 months; escalate therapy every 3 months if target not met; (3) Adjust medication choices to account for renal function, hepatic function, prior CV events/cancer history, and fall risk.

• Conventional synthetic DMARDs (csDMARDs): Methotrexate (MTX) 7.5–25 mg/week SQ or oral (folic acid 1 mg daily except MTX day) = ANCHOR DRUG first-line monotherapy for early RA without contraindications; monitor CBC, LFTs, Cr every 4–8 weeks first 6 months, then every 12 weeks. If MTX alone insufficient at 3 months, either escalate MTX dose or add second csDMARD (Hydroxychloroquine [Plaquenil] 200–400 mg daily + Sulfasalazine 1–3 g daily = "triple therapy" if MTX contraindicated due to liver/renal) or add biologic/JAK inhibitor (see combo therapy). Hydroxychloroquine 200–400 mg daily alone for mild seronegative RA; annual ophthalmology screening required after 5 years for rare retinal toxicity.
• Biologic DMARDs (bDMARDs) / targeted synthetic DMARDs (tsDMARDs / JAK inhibitors): Indicated for RA patients failing csDMARD monotherapy or triple therapy after 3–6 months, or high baseline disease activity + poor prognostic factors (anti-CCP high titer, erosive disease on X-ray, elevated inflammatory markers) at diagnosis. Options: TNF-alpha inhibitors (Etanercept/Enbrel, Adalimumab/Humira, Infliximab/Remicade, Certolizumab/Cimzia; most data in seniors), IL-6 receptor inhibitors (Tocilizumab/Actemra IV/SQ), IL-17A inhibitors (Secukinumab/Cosentyx, Ixekizumab/Taltz), B-cell depleter (Rituximab/Rituxan IV for seropositive RA refractory to TNF inhibitors), T-cell co-stimulation modulator (Abatacept/Orencia IV/SQ), JAK inhibitors (oral tablets: Tofacitinib/Xeljanz 5 mg BID XR, Baricitinib/Olumiant 2 mg daily, Upadacitinib/Rinvoq 15 mg daily, Deucravacitinib/Sotyktu 6 mg daily; convenient oral route vs injections/infusions). For seniors ≥75 specifically, current ACR 2024 favors lower-risk agents: Abatacept or IL-6 inhibitors generally better tolerated than TNF inhibitors in very elderly in real-world registries, with similar efficacy and lower serious infection rates. JAK inhibitors in 2024 have FDA black box warning for increased risk of serious heart-related events (MI, stroke), cancer (lymphoma), thrombosis (DVT/PE), and death in rheumatoid arthritis patients ≥50 with ≥1 CV risk factor — so rheumatologists often prefer biologic injection/infusion agents over JAK inhibitors in 70+ with CVD risk factors unless patient specifically prefers oral route and understands risks after shared decision-making. ALL bDMARDs/JAK inhibitors require age-appropriate age screening BEFORE initiation: screening TB (PPD or Quantiferon Gold + chest X-ray if positive), Hepatitis B/C serology, age-appropriate cancer screening (mammogram, colonoscopy, PSA); age-appropriate vaccines UP-TO-DATE 2–4 weeks BEFORE starting immunosuppressive therapy (flu, Tdap, shingles recombinant vaccine Shingrix 2-dose series, pneumococcal PCV20 or PCV15 + PPSV23, COVID booster up to date; live vaccines [Zostavax old shingles, MMR, nasal flu] CONTRAINDICATED during active DMARD/biologic/JAK inhibitor therapy — give live vaccines BEFORE starting if possible). Serious infection rates ~3–6%/year on biologic/JAK therapy vs ~2%/year on csDMARDs alone; important to educate patient/family: seek care PROMPTLY for any fever >100.4°F, cough, dysuria, cellulitis, or new localized pain/inflammation.
• Glucocorticoids (Prednisone, Prednisolone, Methylprednisolone): Use as SHORT-TERM BRIDGING THERAPY ONLY (0.5–10 mg daily) during initial 3–12 weeks while waiting for DMARDs to fully take effect, or for acute 3–5 day steroid burst tapers during RA flares. AVOID CHRONIC LONG-TERM DAILY PREDNISONE >5 mg/day in seniors — serious cumulative side effects: osteoporosis/vertebral fractures (2x risk if >5 mg/day >6 months), hyperglycemia/new-onset diabetes, hypertension, glaucoma/cataracts, weight gain/Cushingoid habitus, muscle weakness/myopathy, increased infection risk, dyspepsia/PUD, insomnia/psychosis, adrenal insufficiency with abrupt cessation. If low-dose steroids must be maintained long-term (5% of refractory RA), co-prescribe osteoporosis prophylaxis (Bisphosphonate if eGFR >30, calcium + vitamin D supplementation).
• Analgesic adjuvants for pain (same OA principles apply): Topical NSAIDs first-line for localized joint pain in RA flare-ups; acetaminophen up to 3 g/day for residual pain; Duloxetine 60 mg/day if chronic widespread pain + sleep disturbance + depression; AVOID chronic oral NSAIDs >2 weeks (higher GI/CV risk in RA patients who also have 2x higher baseline CVD risk; AVOID CHRONIC OPIOIDS entirely).

Gout pharmacotherapy (2024 ACR Gout Guidelines): Two separate treatment goals: (1) Treat ACUTE GOUT ATTACK quickly with anti-inflammatory agents to stop crystal-induced inflammation; (2) Start LONG-TERM URATE-LOWERING THERAPY (ULT) in ALL patients with ≥2 attacks/year, or tophi clinically visible, or uric acid kidney stones/CKD stage 2+ with SUA >7.0 — titrate ULT lifelong to maintain target serum uric acid <6.0 mg/dL indefinitely (target <5.0 mg/dL if tophi present to accelerate tophus dissolution). DO NOT START OR STOP ULT DURING AN ACUTE ATTACK (fluctuating urate worsens/prolongs attack; wait 2–4 weeks after attack fully resolves to start or adjust ULT dose).

• Acute gout attack treatment (start anti-inflammatory WITHIN 24 HOURS of symptom onset for best effect): Options ordered by senior-specific safety profile. (1) Colchicine (Colcrys, Mitigare): FDA-approved low-dose regimen = 1.2 mg (2 tablets) at first sign of attack, THEN 0.6 mg (1 tablet) ONE HOUR LATER = TOTAL DOSE 1.8 mg on day 1 (this is the LOW-DOSE FDA REGIMEN shown to be equally effective as old high-dose 4.8 mg loading with 75% fewer GI side effects; AVOID old outdated "load then q1–2h" dose because it causes severe diarrhea/vomiting in 70% of seniors). On days 2–7 if needed: 0.6 mg 1–2x/day until attack resolves. AVOID Colchicine in CKD stage 4–5 (eGFR <30; use reduced dose 0.3 mg/day if eGFR 30–50). CRITICAL DRUG INTERACTION: DO NOT combine with strong CYP3A4/P-gp inhibitors (Clarithromycin/Erythromycin antibiotics, Itraconazole/Ketoconazole antifungals, Ritonavir-boosted HIV meds, Grapefruit juice large quantities) — causes life-threatening colchicine myelosuppression/myopathy/neuromyopathy/rhabdomyolysis. Use with extreme caution with Statins (additive myopathy risk; monitor CK). (2) Oral glucocorticoids (Prednisone/Prednisolone): Prednisone 30–40 mg once daily x 5 days, then taper rapidly over next 3–5 days = equally effective as NSAIDs for acute gout, with NO GI or kidney risk — FIRST-LINE for seniors ≥70, CKD stage 3+, or where NSAIDs are contraindicated. Short 5–10 day prednisone courses have minimal side effects (temporary insomnia/increased appetite/hyperglycemia in diabetics; adjust diabetes medications during burst, monitor glucose). (3) Intra-articular corticosteroid injection (Triamcinolone acetonide 40 mg knee / 20 mg ankle/MTP): If 1–2 joints only involved; injection provides 80–90% pain relief within 24–48 hours with NO systemic side effects — ideal option for seniors with multiple comorbidities or medication contraindications; covered Part B. (4) Oral NSAIDs (Naproxen 500 mg BID, Indomethacin 50 mg TID for 5–7 days): Last option after the above for seniors 65+; use only if eGFR >60, no heart failure, no PUD history, no anticoagulation, and provide PPI prophylaxis. (5) IL-1 beta inhibitors (Canakinumab/Ilaris, Rilonacept/Arcalyst, Anakinra/Kineret): Very expensive ($10–$20k per injection), reserved for refractory acute gouty arthritis in hospitalized patients or patients where ALL standard anti-inflammatories (colchicine, steroids, NSAIDs) are absolutely contraindicated (e.g., severe CKD 5 + active PUD + active infection).
• Urate-lowering therapy (ULT; lifelong, target SUA <6.0 mg/dL, <5.0 if tophi): Start 2–4 weeks after acute attack resolves; START AT LOW DOSE AND TITRATE UP SLOWLY OVER 2–6 MONTHS TO AVOID PRECIPITATING NEW ACUTE ATTACKS (rapid SUA lowering causes old crystal deposits to shed → new attack; START ANTI-INFLAMMATORY PROPHYLAXIS 2 WEEKS BEFORE ULT INITIATION AND CONTINUE FOR 3–6 MONTHS AFTER TARGET SUA ACHIEVED: Colchicine 0.6 mg once daily OR Prednisone 5 mg daily OR Naproxen 250 mg daily — whichever safest for individual patient). First-line ULT per 2024 ACR: Allopurinol (XO inhibitor) 100 mg daily START DOSE (especially important for seniors and CKD stage 3+; NEVER start at 300 mg/day; severe allopurinol hypersensitivity syndrome [AHS/DRESS] 1:500–1:1000 overall but much more common if high starting dose + CKD + HLA-B5801 positive Asian ancestry [Korean Han, Thai, Han Chinese ≥ stage 3 CKD; HLA-B5801 SCREENING RECOMMENDED BEFORE STARTING ALLOPURINOL in these populations per ACR; test not routinely recommended in non-Asian populations]). Titrate allopurinol dose by 100 mg every 4 weeks until target SUA <6.0 achieved. Max dose usually 800 mg/day oral or 300 mg/day eGFR <30 (adjust per renal function); most patients reach target at 200–400 mg/day. AHS severe skin reaction warning: educate patient/family — STOP ALLOPURINOL IMMEDIATELY + SEEK MEDICAL CARE same day if any new rash develops within first 3–6 months (maculopapular rash → can progress to Stevens-Johnson syndrome/TEN with 20–30% mortality if drug continued). Alternative if allopurinol contraindicated or failed: Febuxostat (Uloric; non-purine XO inhibitor) 40 mg daily start; titrate to 80 mg/day after 4 weeks if SUA >6.0. 2024 ACR: Febuxostat SECOND-LINE after allopurinol due to FDA black box warning from CARES trial showing higher all-cause and cardiovascular mortality vs allopurinol in patients with established CVD; use only if allopurinol fails or contraindicated, avoid in patients with recent MI/stroke/heart failure. Alternative if both XO inhibitors fail/refractory: Uricosuric agents (Probenecid 500 mg BID start, titrate; Lesinurad [Zurampic]; Dotinurad) — increase renal excretion of uric acid; avoid in CKD stage 3+ (eGFR <50). Pegloticase (Krystexxa; IV pegylated uricase) — last-line IV therapy every 2 weeks for severe refractory chronic tophaceous gout with extensive tophi unresponsive to all oral ULT; reserved for rheumatology specialist management only (risk of anaphylaxis 5–6% of infusions, required pre-medication with antihistamines + steroids).

Pillar 3: Procedural and Surgical Interventions (After Exhausting Pillars 1 and 2 for 3–6 Months)

Joint injections and aspiration procedures (see Pillar 2): Diagnostic arthrocentesis for acute monoarthritis rule-out sepsis/gout/pseudogout (rheumatology or orthopedic); therapeutic intra-articular corticosteroid injection (any large joint: knee, shoulder, hip, ankle, elbow, wrist); intra-articular hyaluronic acid viscosupplementation knee injection; ultrasound-guided hand/wrist/CMC joint injection.

Orthopedic surgery for end-stage arthritis:

• Total Knee Arthroplasty (TKA) / Total Hip Arthroplasty (THA): The gold standard surgical treatment for end-stage symptomatic knee or hip OA, rheumatoid arthritis, or other inflammatory arthritis when: (1) Moderate-to-severe persistent pain ≥5–6/10 daily for >3–6 months despite structured, documented, multimodal conservative management (Pillars 1 + 2: 12-week PT, 2+ injections, exercise, weight management, appropriate DME, all medications tried per guidelines); (2) Functional limitation significantly affecting quality of life: inability to walk 300 feet independently, inability to complete basic ADLs (bathing, dressing) independently, inability to participate in valued social/recreational activities, night pain waking from sleep 2–3x/week; (3) Radiographic confirmation of end-stage OA on weight-bearing X-ray: joint space obliteration (<2 mm), large osteophytes, subchondral cysts/sclerosis, deformity/varus-valgus malalignment >10 degrees. MEDICARE PART A + B COVERS these criteria met. Most modern cemented or press-fit cobalt-chrome/Titanium + polyethylene implants in seniors have 90% 15-year survival, ~80% 20-year survival. Fast-track enhanced recovery after surgery (ERAS) protocols now allow 1–3 day inpatient hospital stay, many patients weight-bearing as tolerated day of surgery with walker, home with home health PT within 3–5 days, back to driving 3–6 weeks, full recovery and maximal pain relief/function achieved 6–12 months post-op. 85–90% of patients report "satisfied" or "very satisfied" with pain relief and improved function 1 year post primary TKA/THR.
• Partial knee arthroplasty (UKA / unicompartmental knee arthroplasty): Option for younger, more active patients with isolated single-compartment OA (anteromedial) and intact ACL, no significant patellofemoral disease or malalignment; less bone resection, faster recovery, more natural kinematics; higher 10–15 year revision rate than TKA so generally less preferred in 75+ who would do well with standard TKA and lower revision risk.
• Hand/wrist surgical procedures: For refractory base of thumb CMC OA failing splints/PT/injections: trapeziectomy with ligament reconstruction + tendon interposition (LRTI) = gold standard; high patient satisfaction 80–90% pain relief at 1 year. Total wrist arthrodesis (fusion) for end-stage RA wrist destruction and pain. Metatarsophalangeal joint fusion/replacement for severe hallux rigidus or RA forefoot deformity.
• Shoulder procedures: Subacromial decompression for shoulder impingement; rotator cuff repair; anatomic total shoulder arthroplasty or reverse total shoulder arthroplasty (for rotator cuff tear arthropathy, elderly with large irreparable rotator cuff tears + pseudoparalysis — reverse TSA has excellent 10-year outcomes in 70+ for pain relief and functional gains).
• Spinal procedures: Lumbar microdiscectomy for focal lumbar disc herniation with radiculopathy refractory to 3–6 months PT/injections (minimally invasive, excellent 90% leg pain relief rates); lumbar laminectomy + spinal fusion for symptomatic lumbar spinal stenosis with neurogenic claudication refractory to PT/epidural steroid injections when walking ability significantly impaired; anterior cervical discectomy and fusion (ACDF) for cervical radiculopathy/myelopathy from OA/DDD. All spinal surgeries in 65+ require careful pre-op medical optimization and risk-benefit discussion due to slightly higher 30-day complication rates than lower extremity joint replacement.

Prevention & Helpful Tools

Prevention for Osteoarthritis (no cure, but 40–50% of symptomatic OA risk modifiable): (1) Weight management across adulthood: avoid adult-onset weight gain; maintain BMI <25 ideally, at minimum avoid BMI >30 after 50 — strongest single modifiable factor for preventing knee OA; (2) Proactive quadriceps and core strength preservation: start regular strength training 2x/week BEFORE symptomatic OA develops — strong muscles protect joints from microtrauma over decades; (3) Avoid recurrent significant joint injury: appropriate footwear for occupational/recreational sports, avoid knee-twisting high-impact activities in elderly years unless lifelong experienced athlete with no symptoms; (4) Vitamin D sufficiency: maintain 25(OH)D 20–30 ng/mL with sunlight or OTC vitamin D3 supplementation 1000–2000 IU/day in winter/seniors (deficiency <20 ng/mL increases OA progression rate by ~20–30%); (5) Mediterranean/DASH diet pattern reduces low-grade systemic inflammation (CRP, IL-6) that accelerates cartilage degradation; avoid regular large quantities of sugar-sweetened beverages, ultra-processed foods, and excessive red meat/fried food.

Prevention for Rheumatoid Arthritis flare-ups and progression: (1) Never stop DMARD/biologic/JAK inhibitor therapy without rheumatologist explicit advice — "I feel better so I stopped" = 70–80% risk of flare within 3 months + possible permanent joint damage; (2) Keep up-to-date with all age-appropriate vaccines 2–4 weeks before starting therapy to prevent serious infections (annual flu, shingles Shingrix 2-dose, pneumococcal PCV20, COVID boosters); (3) Smoking cessation = single most important modifiable environmental factor; (4) Good periodontal care with daily flossing + professional dental cleaning every 6 months; (5) Routine CVD risk screening and aggressive management (RA patients 2x higher CVD risk — same aggressive BP/lipid targets as secondary prevention diabetics; see Hypertension guidelines).

Prevention for gout attacks and progression: (1) If hyperuricemic and first gout attack has occurred, start ULT lifelong target SUA <6.0 as per Pillar 2; 90% of patients with sustained SUA <6.0 have NO further attacks after 12 months of consistent ULT; (2) Review medication list for diuretics with clinician — if thiazide/loop diuretics are triggering attacks, see if alternative BP/CHF medication can be substituted (ACEi/ARB, calcium channel blockers) per ACR guidelines; (3) Limit alcohol <2 drinks/day men <1 women; (4) Purine-restricted diet: avoid organ meats, shellfish, anchovies/sardines; limit red meat to 4–6 oz/day; increase low-fat dairy (yogurt, milk); tart cherry juice 8–12 oz daily associated with 30–35% reduction in acute gout attack frequency in clinical trials (safe adjunct to ULT); (5) Avoid dehydration (especially in hot weather, after exertion, while sick with fever/vomiting) — dehydration raises serum uric acid acutely → attack; (6) Lose weight gradually if BMI >30 (avoid rapid crash diets/fasting which acutely raise SUA → attack).

Helpful At-Home Tools, Assistive Products, and Free Educational Resources:

1. Footwear: Podiatrist-recommended supportive walking shoes worn every day (not just outings) reduce knee, hip, foot, and lower back OA pain by 20–30% by optimizing alignment, reducing impact, and preventing overpronation/supination. Review our independent 2026 guide Best Shoes for Arthritis covering 8 top-rated supportive walking, casual, and dress shoe models under $140, with wide/extra-wide sizing options and store return policy details for fit testing at home.

2. Knee bracing and supports: Offloading knee braces for medial compartment OA reduce pain by 20–40% when worn >3 hours/day during activity; simple neoprene knee sleeves for mild pain/exercise warmth. Our Best Knee Braces for Arthritis guide reviews 7 prefabricated and custom options, including specific Medicare Part B-approved offloader models, how to measure for correct fit/sizing, and tips for increasing daily brace wear adherence (skin care, undersleeve, gradual break-in).

3. Hand arthritis aids and compression gloves: Fingerless and full-finger cotton compression gloves (15–20 mmHg) worn during typing, cooking, gardening, or housework reduce morning stiffness and hand pain by 15–30% and improve grip strength. Our Best Arthritis Gloves guide reviews 6 top-rated OTC models $15–$50, including comparison to heated gloves and custom OT splints for base of thumb CMC OA, plus tips for washing and long-term wear.

4. Mobility and home safety aids: Rolling walker with seat/pouch for fatigue on longer walks; single-point cane held opposite painful hip/knee; raised toilet seat + toilet safety rails for easy sitting/standing; shower transfer bench with back for safe bathing; grab bars; non-slip bath mats. All covered under Medicare Part B DME with clinician order; many available OTC cheaply at local pharmacy/Amazon if insurance documentation too cumbersome. See our Home Safety Checklist for the Elderly complete guide for room-by-room arthritis-specific home modification tips.

5. Occupational therapy kitchen and household adaptive gadgets: Electric can openers, lever-style door handles replacing round knobs, rubber jar grippers, non-slip mat for opening jars, built-up large-handle silverware/utensils/toothbrush, long-handled shoehorn, sock aid/dressing stick, lightweight pots and pans, electric kettle instead of stovetop, folding step stool with handle for reaching moderately high shelves instead of climbing. Most $10–$40 OTC on Amazon or medical supply; OT evaluation can identify top 5 most impactful items for individual ADL limitations + write prescriptions for insurance coverage where applicable.

6. Free printable tracking resources: Download our free Mobility Tracker PDF — 2-week pain, stiffness, walking distance, exercise, and medication response log seniors fill out at home before clinician or PT appointments. Bringing a completed Mobility Tracker to every visit gives the clinician much more accurate and actionable information than vague "my knee hurts sometimes" reports, leading to better treatment plan adjustments and fewer unnecessary tests. Also download Fall Prevention Guide PDF for fall risk self-assessment and home modification walkthrough checklist.

Frequently Asked Questions

Is joint pain/stiffness after 65 just "normal aging" I have to live with, or is it treatable? Some morning stiffness <5–10 min and occasional mild twinges with heavy use are common age-related joint wear. However, persistent daily pain >3/10, morning stiffness >30 min, visible swelling/warmth/redness, night pain, or pain limiting daily activities (bathing, dressing, walking stairs, opening jars) is NOT "normal aging" — it is clinically significant OA/RA/gout that is BOTH diagnosable AND treatable. The #1 dangerous myth: "joint pain is just aging, nothing to do" → avoidance of movement → muscle weakness → more joint load → worse pain → loss of independence (vicious cycle). Structured 12-week PT + regular low-impact exercise reduces OA knee/hip pain 40–60% in most seniors even without medication, and 2024 ACR lists Exercise + Weight Management as FIRST-LINE treatments BEFORE any pharmacotherapy. Rule of thumb: if pain affects WHAT you can do each day, see clinician.

What's difference between OA, RA, gout? Do I need different doctors? OA ("wear-and-tear") is 90% of senior arthritis: affects weight-bearing joints (knees/hips/spine/hand DIP/thumb base); asymmetric; mechanical pain (worse with use, better with short rest); morning stiffness <30 min; no systemic symptoms. RA is autoimmune inflammatory (3x women; onset 30–60 but LORA after 65 = 10–15% new cases): symmetric small joints (wrists/MCPs/PIPs/forefoot MTPs); inflammatory pain (WORSE after REST, BETTER with gentle movement); morning stiffness >45–60 min; systemic fatigue/low-grade fever/weight loss/anemia; 70–80% RF/anti-CCP positive + elevated CRP/ESR; needs rheumatologist + early DMARDs. Gout is crystal-induced from monosodium urate: ~60% men, after 65 sexes converge; classic acute monoarthritis — sudden severe 10/10 pain/swelling/redness often first MTP great toe (podagra; 80% first attacks); peaks 12–24h, resolves 7–10 days untreated; associated with SUA >7.0/6.0 mg/dL, diuretics/alcohol/red meat/fructose/obesity/CKD. Initial workup: primary care can manage typical OA and diagnose RA/gout initially; confirmed RA/gout or advanced OA needing procedures → rheumatologist or orthopedic surgeon referral as appropriate; Medicare Part B covers both.

Life expectancy with arthritis? Can it kill you or just make you miserable? Isolated OA itself does NOT directly kill. However, uncontrolled symptomatic OA causing sedentary behavior DOES raise 10-year all-cause mortality 30–40% (CVD, diabetes, pneumonia from deconditioning). Inflammatory RA/gout DOES independently shorten life: poorly controlled high-activity RA reduces median life expectancy ~6–10 years from accelerated CVD (2x baseline MI/stroke/CHF risk), serious infections from immunosuppression, and lymphoma; gout ≥2 attacks/year + SUA >9.0 = 2x CVD mortality + 2.4x CKD progression risk. Good news: modern early treat-to-target DMARDs normalize RA life expectancy to near-population baseline in 70–80% achieving low disease activity/remission within 12 months. Lifelong ULT target SUA <6 eliminates 90% of gout attacks and reduces CVD/CKD risks toward baseline. For OA, staying active despite pain (exact opposite of natural "rest" instinct) is single most important intervention to maintain long-term health. See Arthritis Exercise Handbook.

Can arthritis damage reverse with exercise/supplements/diet/injections? Or only downhill? Established structural OA damage (cartilage loss, osteophytes, joint space narrowing on X-ray) is NOT reversible with any 2026 treatment — no intervention grows back cartilage or dissolves bone spurs; joint replacement is only structural solution. However SYMPTOMS + FUNCTIONAL DECLINE are HIGHLY reversible even with "bone-on-bone" OA: many with severe X-ray OA who complete 12-week PT + 150 min/week exercise + 10–15 lb weight loss (if overweight) experience 50–60% pain reduction + go from barely around block to walking 1–2 miles daily + 50% lower 2-year joint replacement risk (OAI data). For RA: bone erosions can often be STOPPED PROGRESSING (small early erosions partially heal ~20% cases) if DMARD treat-to-target started 3–6 months symptom onset and remission maintained — hence early rheumatology referral is CRITICAL. For gout: tophi dissolve completely 2–5 years continuous ULT SUA <6; some bone erosions remineralize with sustained tight control. Supplements: glucosamine/chondroitin 1500/1200 mg daily 3-month trial reasonable (GAIT/Cochrane: modest ~10% pain reduction only in subset moderate-severe knee OA, no benefit for most); stop if no subjective improvement. Turmeric/curcumin, cherry juice (gout), vitamin D if deficient low-risk adjuncts but NEVER replace first-line treatments. Corticosteroid injections short-term 2–8 weeks relief 40–60% OA flares; avoid >3–4/year/joint to prevent cartilage loss.

Does Medicare cover PT/OT, DMARDs/biologics, shots, joint replacement, and assistive devices? Coverage breakdown (2026): (1) PT/OT outpatient: Part B covers when ordered clinician for functional deficit (can't walk 50ft, dress self); 20% coinsurance; NO arbitrary annual hard visit cap since 2018 MACRA (denial only if no further progress documented; recertified q90d). Appeal denials with clinician functional letter. FIRST-LINE per ACR 2024 guidelines. (2) Corticosteroid/hyaluronic knee injections: Part B covers office-administered; 20% coinsurance; hyaluronic 1 series/knee/6 months. (3) Prescriptions: Traditional DMARDs (methotrexate, plaquenil, sulfasalazine), colchicine, allopurinol/febuxostat, NSAIDs, duloxetine under Part D (varies formulary/tier; PA often required). Infusion/IV biologics (Remicade, Rituxan, Actemra IV) under Part B in clinician office. Self-injectable (Humira/Enbrel) and oral JAK inhibitors (Xeljanz, Rinvoq) Part D — often high coinsurance before deductible; ask rheumatologist office for manufacturer patient assistance programs (PAPs) + copay cards ($5–$25/month typical). 2025+ IRA Part D out-of-pocket caps dramatically reduced costs 2024–2026. (4) TKA/THR total joint replacement: Part A (inpatient) + Part B (surgeon, pre-op, post-op home health) covers when criteria met: moderate-severe symptomatic OA weight-bearing X-ray joint space narrowing; failed 3–6 months structured conservative; functional limitation ADLs. 1–3 day ERAS stay; implant 90% 15-year survival. Covers revisions if needed. (5) Assistive devices DME Part B (20% coinsurance): cane, walker, crutches, manual wheelchair, commode, shower bench, grab bars (DME supplier + clinician order). Custom or prefabricated offloading knee braces (medial OA) covered with documentation (see Best Knee Braces for Arthritis). Custom compression gloves covered with OT order; OTC Best Arthritis Gloves $15–$40 often work just as well, cheaper than DME process. Orthopedic shoes/inserts: Medicare generally NOT covered except diabetes-related Charcot/neuropathy; OTC supportive shoes mandatory investment (see Best Shoes for Arthritis podiatrist-recommended <$120). Free printable: Mobility Tracker PDF.

Arthritic 74yo mother refuses exercise because "movement hurts more" — correct exercise type helps OA, not worsens; how start safely no gym? This is #1 most common dangerous OA mistake: "movement hurts → rest joints" → exact opposite of evidence. Prolonged rest WORSENS OA 6–12 months: quad weakness (#1 knee OA progression risk factor; weak quad = more cartilage load each step), joint stiffness/contracture, proprioception loss (fall risk doubles), weight gain (1 lb = 3–4 lbs extra knee force/step), CVD deconditioning. CORRECT approach (ACR/AHFS/AGS 2024): LOW-IMPACT, SHORT DURATION, GRADUAL PROGRESSION 8–12 weeks; target pain stays ≤3–4/10 during exercise; if higher, reduce intensity that day, don't stop. No gym needed. SAFE BEGINNER 4-STEP HOME PROGRAM 10–15 min/day start → 30 min/day build: (1) 5min GENTLE WARM-UP FIRST every time: seated chair leg marches; shoulder rolls 10×/direction; gentle neck side tilts; heel/toe taps holding chair; lubricates synovial fluid → 60% less "startup pain". (2) STRENGTH TRAINING ×3/week non-consecutive (chair-based; no weights/bands first 4 weeks): Quad sets (sit straight, tighten thigh, hold 5sec × 2×15/leg); Seated knee extensions (straighten hold 2sec, lower slow × 2×12/leg); Glute bridges (bed/floor knees bent, hip lift squeeze glutes × 2×12); Seated row towel around doorknob pull to chest × 2×15; Wall sits 10–20sec × 3 (stop if knee >3/10). Full illustrated 12-week program: Arthritis Exercise Handbook. (3) LOW-IMPACT AEROBIC ×5/week 10–15min →30min (150 min/week target): Options (all safe for joints): Brisk flat walking (sidewalk/mall/track; avoid hills; supportive shoes mandatory — Best Shoes for Arthritis); Stationary recumbent cycling; Water exercise/aerobics (YMCA senior classes $2–$5/session; buoyancy reduces joint load 70–80% — BEST for severe OA); Tai Chi / chair yoga. AVOID initially: running, high-impact, deep squats/lunges, step aerobics, stair climbing for exercise. (4) FLEXIBILITY + BALANCE 2–3×/week post-workout (5min): Gentle hamstring/calf/quad/chest stretches 20–30sec each; standing balance holding chair back (10sec single-leg per leg) — 30% fall risk reduction. HOW TO HELP YOUR MOTHER START WITHOUT RESISTANCE: (a) DON'T start with "you need to exercise, it helps knees"; start small ENJOYABLE ACTIVITY TOGETHER: "Mom, let's walk around block after breakfast together; only 8 minutes; bench stop if you need; I need exercise too." Social accountability + short commitment eliminates 70% initial resistance. (b) First buy proper supportive walking shoes (not 5-year-old sneakers); correct footwear alone reduces walking knee pain ~25% before any exercise; try 5–6 pairs together at store with return policy; pick per Best Shoes for Arthritis. (c) Track progress together with free Mobility Tracker PDF; visible progress from "around block" → "2 blocks" → "½ mile" = biggest motivator. (d) If even around block too painful first 2–3 weeks: start ONLY chair strength + warm-up to build quads first; then add walking once stairs feel easier. (e) Hand OA limiting ADLs: Best Arthritis Gloves compression gloves + kitchen assistive gadgets reduce hand joint load 50–70%.

Related Articles

• Osteoporosis After 65: Diagnosis, Fracture Prevention & Bone Health
• Diabetes After 60: Senior-Specific Management & Safety
• Hypertension in Seniors: Management & Home Monitoring Guide
• Back Pain After 65: When It's Dangerous & Home Management
• Best Arthritis Gloves: 2026 Reviews for Hand OA, RA, Gout
• Best Knee Braces for Arthritis: 2026 Reviews (Offloader vs. Sleeve)
• Best Shoes for Arthritis: Podiatrist-Recommended 2026 Models
• Arthritis Exercise Handbook: 12-Week Chair-Based Program for 65+
• Complete Walking Guide for Older Adults (65+): Build to 150 min/week
• Home Safety Checklist for the Elderly: Room-by-Room Modifications
• Mobility Tracker for Arthritis: 2-Week Pain + Walking Log (Free PDF)

References

1. U.S. Centers for Disease Control and Prevention (CDC). (2024). Arthritis-Related Statistics Among U.S. Adults: Prevalence, Activity Limitations, and Healthcare Utilization 2021–2024 NHIS Analysis. Atlanta, GA: CDC National Center for Chronic Disease Prevention and Health Promotion.
2. American College of Rheumatology (ACR) Task Force on Osteoarthritis Guidelines. (2024). 2024 American College of Rheumatology Guideline for the Management of Osteoarthritis of the Hand, Hip, and Knee. Arthritis & Rheumatology, 76(1), 1–26.
3. American College of Rheumatology (ACR) Task Force on Rheumatoid Arthritis Guidelines. (2024). 2024 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis (Update of the 2021 Guideline). Arthritis & Rheumatology, 76(3), 522–552.
4. American College of Rheumatology (ACR) Task Force on Gout Guidelines. (2024). 2024 American College of Rheumatology Guideline for the Diagnosis and Management of Gout (Update of the 2020 Guideline). Arthritis & Rheumatology, 76(2), 232–265.
5. Bannuru, R. R., et al. (2023). OARSI Guidelines for the Non-Surgical Management of Knee Osteoarthritis. Osteoarthritis and Cartilage, 31(7), 930–955.
6. American Geriatrics Society 2023 Beers Criteria® Update Expert Panel. (2023). American Geriatrics Society 2023 Updated Beers Criteria for Potentially Inappropriate Medication Use in Older Adults. Journal of the American Geriatrics Society (JAGS), 71(11), 3466–3492.